Verve won tri­al suc­cess with a gene-edit­ing mile­stone. Why don't in­vestors like it?

This week­end, Verve Ther­a­peu­tics pre­sent­ed the first-ever re­sults of an in vi­vo base edit­ing ther­a­py in hu­mans, mark­ing a ma­jor mile­stone not on­ly for the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER